TriangleNCT04689828 · MORE INFO
Limitations, agreements, and source contact
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- certain Agreement
- other Details
- The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of pooled data (i.e.,data from all sites) in clinical trial or disclosure of trial results in their entirety.
- pi Sponsor Employee
- false
- restriction Type
- OTHER
- restrictive Agreement
- true
- limitations And Caveats
- description
- 235 participants were randomized to the AAA617 arm and 234 to the ARDT arm. However, only 228 participants in the AAA617 arm and 232 in the ARDT arm received at least one dose of study treatment. Additionally, 1 participant in the AAA617 arm was excluded from the safety analysis set due to a protocol violation, which means only 227 participants were included in the safety analysis set for this arm.
- point Of Contact
- novartis.email@novartis.com
- organization
- Novartis Pharmaceuticals
- phone
- 862-778-8300
- title
- Study Director
Complete source fields
- certain Agreement
- other Details
- The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of pooled data (i.e.,data from all sites) in clinical trial or disclosure of trial results in their entirety.
- pi Sponsor Employee
- false
- restriction Type
- OTHER
- restrictive Agreement
- true
- limitations And Caveats
- description
- 235 participants were randomized to the AAA617 arm and 234 to the ARDT arm. However, only 228 participants in the AAA617 arm and 232 in the ARDT arm received at least one dose of study treatment. Additionally, 1 participant in the AAA617 arm was excluded from the safety analysis set due to a protocol violation, which means only 227 participants were included in the safety analysis set for this arm.
- point Of Contact
- novartis.email@novartis.com
- organization
- Novartis Pharmaceuticals
- phone
- 862-778-8300
- title
- Study Director
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice